These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32227432)

  • 21. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
    Wanner C; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; George JT; von Eynatten M; Hauske SJ;
    Diabetes Obes Metab; 2020 Dec; 22(12):2335-2347. PubMed ID: 32744354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
    Inzucchi SE; Zinman B; Fitchett D; Wanner C; Ferrannini E; Schumacher M; Schmoor C; Ohneberg K; Johansen OE; George JT; Hantel S; Bluhmki E; Lachin JM
    Diabetes Care; 2018 Feb; 41(2):356-363. PubMed ID: 29203583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
    Coleman RL; Gray AM; Broedl Md UC; Fitchett D; George JT; Woerle HJ; Zinman B; Holman RR
    Diabetes Obes Metab; 2020 Jul; 22(7):1151-1156. PubMed ID: 32115840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　- Results From EMPA-REG OUTCOME
    Kaku K; Lee J; Mattheus M; Kaspers S; George J; Woerle HJ;
    Circ J; 2017 Jan; 81(2):227-234. PubMed ID: 28025462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
    Langslet G; Nyström T; Vistisen D; Carstensen B; Grip ET; Casajust P; Tskhvarashvili G; Hoti F; Klement R; Karlsdotter K; Tuovinen M; Ofstad AP; Lajer M; Shay C; Koeneman L; Farsani SF; Niskanen L; Halvorsen S
    J Diabetes Res; 2024; 2024():6142211. PubMed ID: 39430801
    [No Abstract]   [Full Text] [Related]  

  • 26. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
    Zinman B; Inzucchi SE; Lachin JM; Wanner C; Ferrari R; Fitchett D; Bluhmki E; Hantel S; Kempthorne-Rawson J; Newman J; Johansen OE; Woerle HJ; Broedl UC
    Cardiovasc Diabetol; 2014 Jun; 13():102. PubMed ID: 24943000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
    Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT
    J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
    Anker SD; Sander LE; Fitchett DH; Zinman B; Pernille Ofstad A; Wanner C; Vedin O; Lauer S; Verma S; Yaggi HK; Inzucchi SE
    Diabetes Res Clin Pract; 2022 Apr; 186():109837. PubMed ID: 35314257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
    Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
    J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
    Böhm M; Fitchett D; Ofstad AP; Brueckmann M; Kaspers S; George JT; Zwiener I; Zinman B; Wanner C; Marx N; Mancia G; Anker SD; Mahfoud F
    J Hypertens; 2020 Sep; 38(9):1829-1840. PubMed ID: 32618884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Fitchett D; Ofstad AP; Kraus BJ; Wanner C; Zwiener I; Zinman B; Lauer S; George JT; Rossignol P; Zannad F
    Am J Hypertens; 2020 Dec; 33(12):1092-1101. PubMed ID: 32369546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
    Wong ND; Fan W; Pak J
    Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF
    Elharram M; Ferreira JP; Huynh T; Ni J; Giannetti N; Verma S; Zannad F; Sharma A
    Diabetes Obes Metab; 2021 Mar; 23(3):782-790. PubMed ID: 33269511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME
    Langslet G; Zinman B; Wanner C; Hantel S; Espadero RM; Fitchett D; Johansen OE
    Diab Vasc Dis Res; 2020; 17(6):1479164120975256. PubMed ID: 33307785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
    Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B;
    Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
    Neeland IJ; Eliasson B; Kasai T; Marx N; Zinman B; Inzucchi SE; Wanner C; Zwiener I; Wojeck BS; Yaggi HK; Johansen OE;
    Diabetes Care; 2020 Dec; 43(12):3007-3015. PubMed ID: 33004464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
    Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
    Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.